Evidence map›Paper›PMID 33536025›Full record

ArticleMicrobial cell factories2021

Engineering of Saccharomyces cerevisiae for anthranilate and methyl anthranilate production.

Joosu Kuivanen, Matti Kannisto, Dominik Mojzita, Heiko Rischer, Mervi Toivari, Jussi Jäntti

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Functional dissection ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. A comprehensive review and comparison of L-tryptophan biosynthesis inFrontiers in bioengineering and biotechnology · 2023
    Review
  10. EngineeredFrontiers in microbiology · 2023
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Joosu KuivanenVTT Technical Research Centre of Finland Ltd, Espoo, Finland.
Matti KannistoVTT Technical Research Centre of Finland Ltd, Espoo, Finland. Matti.Kannisto@vtt.fi.ORCID http://orcid.org/0000-0003-1057-0229
Dominik MojzitaVTT Technical Research Centre of Finland Ltd, Espoo, Finland.
Heiko RischerVTT Technical Research Centre of Finland Ltd, Espoo, Finland.
Mervi ToivariVTT Technical Research Centre of Finland Ltd, Espoo, Finland.
Jussi JänttiVTT Technical Research Centre of Finland Ltd, Espoo, Finland.
VTT Technical Research Centre of Finland · FIMSD (Finland) · FI

Funding

The Novo Nordisk Foundation NNF17OC0025726
6 · The paper itself

Abstract

backgroundAnthranilate is a platform chemical used by the industry in the synthesis of a broad range of high-value products, such as dyes, perfumes and pharmaceutical compounds. Currently anthranilate is produced via chemical synthesis from non-renewable resources. Biological synthesis would allow the use of renewable carbon sources and avoid accumulation of toxic by-products. Microorganisms produce anthranilate as an intermediate in the tryptophan biosynthetic pathway. Several prokaryotic microorganisms have been engineered to overproduce anthranilate but attempts to engineer eukaryotic microorganisms for anthranilate production are scarce.

resultsWe subjected Saccharomyces cerevisiae, a widely used eukaryotic production host organism, to metabolic engineering for anthranilate production. A single gene knockout was sufficient to trigger anthranilate accumulation both in minimal and SCD media and the titer could be further improved by subsequent genomic alterations. The effects of the modifications on anthranilate production depended heavily on the growth medium used. By growing an engineered strain in SCD medium an anthranilate titer of 567.9 mg l

conclusionsIn this study we have engineered metabolism of S. cerevisiae for improved anthranilate production. The resulting strains may serve as a basis for development of efficient production host organisms for anthranilate-derived compounds. In order to demonstrate suitability of the engineered S. cerevisiae strains for production of such compounds, we successfully extended the anthranilate biosynthesis pathway to synthesis of methyl anthranilate.

Indexed as

Metabolic EngineeringMicroorganisms, Genetically-Modifiedortho-AminobenzoatesSaccharomyces cerevisiaemethyl anthranilateortho-AminobenzoatesAnthranilateMetabolic engineeringMethyl anthranilateSaccharomyces cerevisiaeShikimate pathway

Identifiers

PMID33536025
PMCPMC7860014
OpenAlexW3127526656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.